Prostate Cancer

Restricted access
In the late 1980s and early 1990s, the number of newly diagnosed prostate cancers in the United States increased dramatically, surpassing lung cancer as the most common cancer in men.1 Experts generally believe that these changes resulted from prostate-specific antigen (PSA) screening that detected many early-stage prostate cancers. For example, the percentage of patients with low-risk disease has increased (45.3% in 1999–2001 vs. 29.8% in 1989–1992; P < .0001).2 The incidence of prostate cancer increased 2.0% annually from 1995 to 2001 and has since declined. In 2009, an estimated 192,280 new cases were diagnosed and prostate cancer was expected to account for 25% of new cancer cases in men.1 Fortunately, the age-adjusted death rates from prostate cancer have also declined (–4.1% annually from 1994 to 2001).1 Researchers expect prostate cancer to account for 27,360 deaths in 2009.1 This comparatively low death rate suggests that, unless prostate cancer is becoming biologically less aggressive, increased public awareness with earlier detection and treatment of prostate cancer has begun to affect mortality from this prevalent cancer. However, early detection and treatment of prostate cancers that do not threaten life expectancy cause unnecessary side effects that impair quality of life, increase health care expenses, and decrease the value of PSA and digital rectal examination (DRE) as early detection tests.3,4To properly identify and manage patients with prostate cancer or any other malignancy, physicians must have an in-depth understanding of the natural history and diagnostic, staging, and treatment options. To this end, every year the NCCN...
  • 1.

    Jemal A, Siegel R, Ward E. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225249.

  • 2.

    Cooperberg MR, Lubeck DP, Meng MV. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004;22:21412149.

    • Search Google Scholar
    • Export Citation
  • 3.

    Andriole GL, Crawford ED, Grubb RL III. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:13101319.

  • 4.

    Schroder FH, Hugosson J, Roobol MJ. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:13201328.

  • 5.

    Social Security Administration. Period Life Table. Available at: http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed January 5, 2010.

    • Search Google Scholar
    • Export Citation
  • 6.

    Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006;295:801808.

    • Search Google Scholar
    • Export Citation
  • 7.

    D'Amico AV, Whittington R, Malkowicz SB. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17:168172.

    • Search Google Scholar
    • Export Citation
  • 8.

    D'Amico AV, Whittington R, Malkowicz SB. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281286.

    • Search Google Scholar
    • Export Citation
  • 9.

    D'Amico AV, Whittington R, Malkowicz SB. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969974.

    • Search Google Scholar
    • Export Citation
  • 10.

    James Buchanan Brady Urological Institute. Johns Hopkins Medicine. The Partin Tables. Available at: http://urology.jhu.edu/prostate/partintables.php. Accessed January 5, 2010.

    • Search Google Scholar
    • Export Citation
  • 11.

    Makarov DV, Trock BJ, Humphreys EB. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:10951101.

    • Search Google Scholar
    • Export Citation
  • 12.

    Kattan MW, Eastham JA, Wheeler TM. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:17921797.

    • Search Google Scholar
    • Export Citation
  • 13.

    Memorial Sloan-Kettering Cancer Center. Prostate Cancer Nomograms. Available at: http://www.mskcc.org/mskcc/html/10088.cfm. Accessed January 5, 2010.

    • Search Google Scholar
    • Export Citation
  • 14.

    Stephenson AJ, Scardino PT, Eastham JA. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715717.

    • Search Google Scholar
    • Export Citation
  • 15.

    Stephenson AJ, Kattan MW, Eastham JA. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:43004305.

    • Search Google Scholar
    • Export Citation
  • 16.

    Graefen M, Haese A, Pichlmeier U. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 2001;165:857863.

    • Search Google Scholar
    • Export Citation
  • 17.

    Ohori M, Kattan MW, Koh H. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004;171:18441849; discussion 1849.

    • Search Google Scholar
    • Export Citation
  • 18.

    Steuber T, Graefen M, Haese A. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006;175:939944; discussion 944.

    • Search Google Scholar
    • Export Citation
  • 19.

    Briganti A, Chun FK, Salonia A. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 2007;51:112119; discussion 119–120.

    • Search Google Scholar
    • Export Citation
  • 20.

    Kattan MW, Potters L, Blasko JC. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393399.

    • Search Google Scholar
    • Export Citation
  • 21.

    Potters L, Morgenstern C, Calugaru E. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008;179:S2024.

    • Search Google Scholar
    • Export Citation
  • 22.

    Zelefsky MJ, Kattan MW, Fearn P. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology 2007;70:283287.

    • Search Google Scholar
    • Export Citation
  • 23.

    Jeldres C, Suardi N, Walz J. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008;54:13061313.

    • Search Google Scholar
    • Export Citation
  • 24.

    Stephenson AJ, Scardino PT, Kattan MW. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:20352041.

    • Search Google Scholar
    • Export Citation
  • 25.

    Dearnaley DP, Khoo VS, Norman AR. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267272.

    • Search Google Scholar
    • Export Citation
  • 26.

    Khoo VS. Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin Oncol (R Coll Radiol) 2005;17:560571.

    • Search Google Scholar
    • Export Citation
  • 27.

    D'Amico AV, Cote K, Loffredo M. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:45674573.

    • Search Google Scholar
    • Export Citation
  • 28.

    D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125135.

    • Search Google Scholar
    • Export Citation
  • 29.

    D'Amico AV, Moul JW, Carroll PR. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:13761383.

    • Search Google Scholar
    • Export Citation
  • 30.

    Sakr WA, Grignon DJ, Crissman JD. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439443.

    • Search Google Scholar
    • Export Citation
  • 31.

    Thompson IM, Pauler DK, Goodman PJ. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:22392246.

    • Search Google Scholar
    • Export Citation
  • 32.

    Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:81658169.

  • 33.

    Draisma G, Etzioni R, Tsodikov A. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374383.

    • Search Google Scholar
    • Export Citation
  • 34.

    Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368374.

    • Search Google Scholar
    • Export Citation
  • 35.

    Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004;101:20012005.

    • Search Google Scholar
    • Export Citation
  • 36.

    Chun FK, Haese A, Ahyai SA. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008;113:701709.

    • Search Google Scholar
    • Export Citation
  • 37.

    Bastian PJ, Carter BH, Bjartell A. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009;55:13211330.

    • Search Google Scholar
    • Export Citation
  • 38.

    Draisma G, Boer R, Otto SJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868878.

    • Search Google Scholar
    • Export Citation
  • 39.

    Lu-Yao GL, Albertsen PC, Moore DF. Outcomes of localized prostate cancer following conservative management. JAMA 2009;302:12021209.

  • 40.

    Sanda MG, Kaplan ID. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA 2009;301:21412151.

  • 41.

    Shappley WV III, Kenfield SA, Kasperzyk JL. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009;27:49804985.

    • Search Google Scholar
    • Export Citation
  • 42.

    Bill-Axelson A, Holmberg L, Filen F. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:11441154.

    • Search Google Scholar
    • Export Citation
  • 43.

    Schroder FH, Roach M III, Scardino P. Clinical decisions. Management of prostate cancer. N Engl J Med 2008;359:26052609.

  • 44.

    Schwartz RS. Clinical decisions. Management of prostate cancer—polling results. N Engl J Med 2009;360:e4.

  • 45.

    Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997;79:235246.

    • Search Google Scholar
    • Export Citation
  • 46.

    Carter HB, Kettermann A, Warlick C. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:23592364; discussion 2364–2355.

    • Search Google Scholar
    • Export Citation
  • 47.

    Choo R, Klotz L, Danjoux C. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167:16641669.

    • Search Google Scholar
    • Export Citation
  • 48.

    Stephenson AJ, Aprikian AG, Souhami L. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002;59:652656.

    • Search Google Scholar
    • Export Citation
  • 49.

    van den Bergh RC, Essink-Bot ML, Roobol MJ. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009;115:38683878.

    • Search Google Scholar
    • Export Citation
  • 50.

    Hanlon AL, Watkins Bruner D, Peter R, Hanks GE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001;49:5159.

    • Search Google Scholar
    • Export Citation
  • 51.

    Koper PC, Stroom JC, van Putten WL. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1999;43:727734.

    • Search Google Scholar
    • Export Citation
  • 52.

    Michalski JM, Bae K, Roach M. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 2010;76:1422.

    • Search Google Scholar
    • Export Citation
  • 53.

    Peeters ST, Heemsbergen WD, Koper PC. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:19901996.

    • Search Google Scholar
    • Export Citation
  • 54.

    Pollack A, Zagars GK, Starkschall G. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:10971105.

    • Search Google Scholar
    • Export Citation
  • 55.

    Zietman AL, DeSilvio ML, Slater JD. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:12331239.

    • Search Google Scholar
    • Export Citation
  • 56.

    Kuban DA, Tucker SL, Dong L. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:6774.

    • Search Google Scholar
    • Export Citation
  • 57.

    Potosky AL, Davis WW, Hoffman RM. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:13581367.

    • Search Google Scholar
    • Export Citation
  • 58.

    D'Amico AV, Manola J, Loffredo M. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821827.

    • Search Google Scholar
    • Export Citation
  • 59.

    Sanda MG, Dunn RL, Michalski J. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:12501261.

    • Search Google Scholar
    • Export Citation
  • 60.

    Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007;110:14171428.

    • Search Google Scholar
    • Export Citation
  • 61.

    Merrick GS, Butler WM, Wallner KE. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004;64:754759.

    • Search Google Scholar
    • Export Citation
  • 62.

    D'Amico AV, Moran BJ, Braccioforte MH. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009;27:39233928.

    • Search Google Scholar
    • Export Citation
  • 63.

    Nag S, Bice W, DeWyngaert K. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000;46:221230.

    • Search Google Scholar
    • Export Citation
  • 64.

    Hartsell WF, Scott CB, Bruner DW. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798804.

    • Search Google Scholar
    • Export Citation
  • 65.

    Konski A, James J, Hartsell W. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am J Clin Oncol 2009;32:423428.

    • Search Google Scholar
    • Export Citation
  • 66.

    Janjan N, Lutz ST, Bedwinek JM. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med 2009;12:417426.

    • Search Google Scholar
    • Export Citation
  • 67.

    Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004;45:13581365.

    • Search Google Scholar
    • Export Citation
  • 68.

    Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:20952101.

    • Search Google Scholar
    • Export Citation
  • 69.

    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975980.

    • Search Google Scholar
    • Export Citation
  • 70.

    Herrell SD, Smith JA Jr. Robotic-assisted laparoscopic prostatectomy: what is the learning curve? Urology 2005;66:105107.

  • 71.

    Smith JA Jr, Herrell SD. Robotic-assisted laparoscopic prostatectomy: do minimally invasive approaches offer significant advantages? J Clin Oncol 2005;23:81708175.

    • Search Google Scholar
    • Export Citation
  • 72.

    Hu JC, Gu X, Lipsitz SR. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009;302:15571564.

  • 73.

    Abel EJ, Masterson TA, Warner JN. Nerve-sparing prostatectomy and urinary function: a prospective analysis using validated quality-of-life measures. Urology 2009;73:13361340.

    • Search Google Scholar
    • Export Citation
  • 74.

    Davis JW, Chang DW, Chevray P. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol 2009;55:11351143.

    • Search Google Scholar
    • Export Citation
  • 75.

    Cagiannos I, Karakiewicz P, Eastham JA. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003;170:17981803.

    • Search Google Scholar
    • Export Citation
  • 76.

    Masterson TA, Bianco FJ Jr, Vickers AJ. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006;175:13201324; discussion 1324–1325.

    • Search Google Scholar
    • Export Citation
  • 77.

    Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68:121125.

    • Search Google Scholar
    • Export Citation
  • 78.

    Allaf ME, Palapattu GS, Trock BJ. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172:18401844.

    • Search Google Scholar
    • Export Citation
  • 79.

    Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849854.

    • Search Google Scholar
    • Export Citation
  • 80.

    Daneshmand S, Quek ML, Stein JP. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172:22522255.

    • Search Google Scholar
    • Export Citation
  • 81.

    Wagner M, Sokoloff M, Daneshmand S. The role of pelvic lymphadenectomy for prostate cancer—therapeutic? J Urol 2008;179:408413.

  • 82.

    Labrie F, Dupont A, Belanger A, Lachance R. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 1987;138:804806.

    • Search Google Scholar
    • Export Citation
  • 83.

    Schulze H, Senge T. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 1990;144:934941.

    • Search Google Scholar
    • Export Citation
  • 84.

    Iversen P, Johansson JE, Lodding P. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 2006;40:441452

    • Search Google Scholar
    • Export Citation
  • 85.

    Bolla M, Collette L, Blank L. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103106.

    • Search Google Scholar
    • Export Citation
  • 86.

    Kumar S, Shelley M, Harrison C. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;(4):CD006019.

    • Search Google Scholar
    • Export Citation
  • 87.

    Shelley MD, Kumar S, Wilt T. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:917.

    • Search Google Scholar
    • Export Citation
  • 88.

    Bolla M, Gonzalez D, Warde P. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295300.

    • Search Google Scholar
    • Export Citation
  • 89.

    Denham JW, Steigler A, Lamb DS. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841850.

    • Search Google Scholar
    • Export Citation
  • 90.

    Loblaw DA, Virgo KS, Nam R. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:15961605.

    • Search Google Scholar
    • Export Citation
  • 91.

    Messing EM, Manola J, Yao J. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472479.

    • Search Google Scholar
    • Export Citation
  • 92.

    Wong YN, Freedland S, Egleston B. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009;27:100105.

  • 93.

    McLeod DG, Iversen P, See WA. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97:247254.

    • Search Google Scholar
    • Export Citation
  • 94.

    McLeod DG, See WA, Klimberg I. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol 2006;176:7580.

    • Search Google Scholar
    • Export Citation
  • 95.

    Lu-Yao GL, Albertsen PC, Moore DF. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173181.

    • Search Google Scholar
    • Export Citation
  • 96.

    Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008;358:14741482.

  • 97.

    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154164.

  • 98.

    Smith MR, Boyce SP, Moyneur E. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175:136139; discussion 139.

    • Search Google Scholar
    • Export Citation
  • 99.

    Smith MR, Lee WC, Brandman J. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:78977903.

    • Search Google Scholar
    • Export Citation
  • 100.

    Daniell HW, Dunn SR, Ferguson DW. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181186.

  • 101.

    Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998;83:15611566.

    • Search Google Scholar
    • Export Citation
  • 102.

    Maillefert JF, Sibilia J, Michel F. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:12191222.

    • Search Google Scholar
    • Export Citation
  • 103.

    Smith MR, McGovern FJ, Zietman AL. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948955.

    • Search Google Scholar
    • Export Citation
  • 104.

    Smith MR, Finkelstein JS, McGovern FJ. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599603.

    • Search Google Scholar
    • Export Citation
  • 105.

    Diamond TH, Winters J, Smith A. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001;92:14441450.

    • Search Google Scholar
    • Export Citation
  • 106.

    Smith MR, Eastham J, Gleason DM. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:20082012.

    • Search Google Scholar
    • Export Citation
  • 107.

    Michaelson MD, Kaufman DS, Lee H. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:10381042.

    • Search Google Scholar
    • Export Citation
  • 108.

    Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146:416424.

    • Search Google Scholar
    • Export Citation
  • 109.

    Smith MR, Egerdie B, Hernandez Toriz N. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745755.

    • Search Google Scholar
    • Export Citation
  • 110.

    Smith MR, Malkowicz SB, Chu F. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179:152155.

    • Search Google Scholar
    • Export Citation
  • 111.

    Smith MR, Malkowicz SB, Chu F. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 2008;26:18241829.

    • Search Google Scholar
    • Export Citation
  • 112.

    Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:44484456.

    • Search Google Scholar
    • Export Citation
  • 113.

    Saigal CS, Gore JL, Krupski TL. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:14931500.

    • Search Google Scholar
    • Export Citation
  • 114.

    D'Amico AV, Denham JW, Crook J. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:24202425.

    • Search Google Scholar
    • Export Citation
  • 115.

    Roach M III, Bae K, Speight J. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585591.

    • Search Google Scholar
    • Export Citation
  • 116.

    Studer UE, Whelan P, Albrecht W. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol 2006;24:18681876.

    • Search Google Scholar
    • Export Citation
  • 117.

    Tsai HK, D'Amico AV, Sadetsky N. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:15161524.

    • Search Google Scholar
    • Export Citation
  • 118.

    Efstathiou JA, Bae K, Shipley WU. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009;27:9299.

    • Search Google Scholar
    • Export Citation
  • 119.

    Berruti A, Dogliotti L, Terrone C. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167:23612367; discussion 2367.

    • Search Google Scholar
    • Export Citation
  • 120.

    Tayek JA, Heber D, Byerley LO. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism 1990;39:13141319.

    • Search Google Scholar
    • Export Citation
  • 121.

    Dockery F, Bulpitt CJ, Agarwal S. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003;104:195201.

    • Search Google Scholar
    • Export Citation
  • 122.

    Smith JC, Bennett S, Evans LM. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:42614267.

    • Search Google Scholar
    • Export Citation
  • 123.

    Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:13051308.

    • Search Google Scholar
    • Export Citation
  • 124.

    Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995;154:100104.

    • Search Google Scholar
    • Export Citation
  • 125.

    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, ed. 7 New York: Springer-Verlag; 2009.

  • 126.

    College of American Pathologists. Cancer Protocols and Checklists: Prostate Gland. Available at: http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2006/prostate06_pw.pdf. Accessed January 5, 2010.

    • Search Google Scholar
    • Export Citation
  • 127.

    Wolf JS Jr, Cher M, Dall'era M. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995;153:993999.

    • Search Google Scholar
    • Export Citation
  • 128.

    Chodak GW, Thisted RA, Gerber GS. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242248.

  • 129.

    Johansson JE, Andren O, Andersson SO. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713-2719.

  • 130.

    Gore JL, Kwan L, Lee SP. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst 2009;101:888892.

    • Search Google Scholar
    • Export Citation
  • 131.

    Babaian RJ, Donnelly B, Bahn D. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008;180:19932004.

    • Search Google Scholar
    • Export Citation
  • 132.

    Johansson JE, Holmberg L, Johansson S. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277:467471.

    • Search Google Scholar
    • Export Citation
  • 133.

    D'Amico AV, Chen MH, Renshaw AA. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289295.

    • Search Google Scholar
    • Export Citation
  • 134.

    Widmark A, Klepp O, Solberg A. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301308.

    • Search Google Scholar
    • Export Citation
  • 135.

    Horwitz EM, Bae K, Hanks GE. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:24972504.

    • Search Google Scholar
    • Export Citation
  • 136.

    Bolla M, de Reijke TM, Van Tienhoven G. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:25162527.

    • Search Google Scholar
    • Export Citation
  • 137.

    Lau WK, Bergstralh EJ, Blute ML. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 2002;167:117122.

    • Search Google Scholar
    • Export Citation
  • 138.

    Klotz L. Point: active surveillance for favorable risk prostate cancer. J Natl Compr Canc Netw 2007;5:693698.

  • 139.

    Pound CR, Partin AW, Eisenberger MA. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:15911597.

    • Search Google Scholar
    • Export Citation
  • 140.

    Thompson IM, Tangen CM, Paradelo J. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956962.

    • Search Google Scholar
    • Export Citation
  • 141.

    Thompson IM Jr, Tangen CM, Paradelo J. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:23292335.

    • Search Google Scholar
    • Export Citation
  • 142.

    Swanson GP, Goldman B, Tangen CM. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol 2008;180:24532457; discussion 2458.

    • Search Google Scholar
    • Export Citation
  • 143.

    Van der Kwast TH, Bolla M, Van Poppel H. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007;25:41784186.

    • Search Google Scholar
    • Export Citation
  • 144.

    Wiegel T, Bottke D, Steiner U. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:29242930.

    • Search Google Scholar
    • Export Citation
  • 145.

    Cheung R, Kamat AM, de Crevoisier R. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 2005;63:134140.

    • Search Google Scholar
    • Export Citation
  • 146.

    Lee AK, D'Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 2005;23:81928197.

    • Search Google Scholar
    • Export Citation
  • 147.

    Patel R, Lepor H, Thiel RP, Taneja SS. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy. Urology 2005;65:942946.

    • Search Google Scholar
    • Export Citation
  • 148.

    Stephenson AJ, Shariat SF, Zelefsky MJ. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:13251332.

    • Search Google Scholar
    • Export Citation
  • 149.

    Ward JF, Zincke H, Bergstralh EJ. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004;172:22442248.

    • Search Google Scholar
    • Export Citation
  • 150.

    Trock BJ, Han M, Freedland SJ. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:27602769.

    • Search Google Scholar
    • Export Citation
  • 151.

    Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 1999;54:884890.

    • Search Google Scholar
    • Export Citation
  • 152.

    Cher ML, Bianco FJ Jr, Lam JS. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:13871391.

    • Search Google Scholar
    • Export Citation
  • 153.

    Roach M III, Hanks G, Thames H Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965974.

    • Search Google Scholar
    • Export Citation
  • 154.

    Rogers E, Ohori M, Kassabian VS. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995;153:104110.

    • Search Google Scholar
    • Export Citation
  • 155.

    Shekarriz B, Upadhyay J, Pontes JE. Salvage radical prostatectomy. Urol Clin North Am 2001;28:545553.

  • 156.

    Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007;100:760764.

    • Search Google Scholar
    • Export Citation
  • 157.

    Allen GW, Howard AR, Jarrard DF, Ritter MA. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer 2007;110:14051416.

    • Search Google Scholar
    • Export Citation
  • 158.

    Pucar D, Shukla-Dave A, Hricak H. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005;236:545553.

    • Search Google Scholar
    • Export Citation
  • 159.

    Westphalen AC, Kurhanewicz J, Cunha RM. T2-weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. Int Braz J Urol 2009;35:171180; discussion 181–172.

    • Search Google Scholar
    • Export Citation
  • 160.

    Sella A, Konichezky M, Flex D. Low PSA metastatic androgen-independent prostate cancer. Eur Urol 2000;38:250254.

  • 161.

    Dupont A, Gomez JL, Cusan L. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993;150:908913.

    • Search Google Scholar
    • Export Citation
  • 162.

    Sartor AO, Tangen CM, Hussain MH. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008;112:23932400.

    • Search Google Scholar
    • Export Citation
  • 163.

    Small EJ, Halabi S, Dawson NA. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:10251033.

    • Search Google Scholar
    • Export Citation
  • 164.

    Petrylak DP, Tangen CM, Hussain MH. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:15131520.

    • Search Google Scholar
    • Export Citation
  • 165.

    Tannock IF, de Wit R, Berry WR. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:15021512.

    • Search Google Scholar
    • Export Citation
  • 166.

    Berthold DR, Pond GR, Soban F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242245.

    • Search Google Scholar
    • Export Citation
  • 167.

    Machiels JP, Mazzeo F, Clausse M. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008;26:52615268.

    • Search Google Scholar
    • Export Citation
  • 168.

    Kantoff PW, Schuetz T, Blumenstein BA. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 5013.

    • Search Google Scholar
    • Export Citation
  • 169.

    Schellbammer PF, Higano C, Berger ER. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC) [abstract]. Presented at the American Urological Association Annual Meeting 2009. April 25–30, 2009; Chicago, Illinois. Late-breaking Abstract 9.

    • Search Google Scholar
    • Export Citation
  • 170.

    Saad F, Gleason DM, Murray R. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:14581468.

    • Search Google Scholar
    • Export Citation
  • 171.

    Saad F, Gleason DM, Murray R. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879882.

    • Search Google Scholar
    • Export Citation
  • 172.

    Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:11151117.

    • Search Google Scholar
    • Export Citation
  • 173.

    Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:12381239.

    • Search Google Scholar
    • Export Citation
  • 174.

    Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008;98:17361740.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3179 2713 281
PDF Downloads 571 494 59
EPUB Downloads 0 0 0